Lasofoxifene - Sermonix Pharmaceuticals

Drug Profile

Lasofoxifene - Sermonix Pharmaceuticals

Alternative Names: CP-336156; CP-336156-CB; Fablyn; Lasofoxifene tartrate; Oporia

Latest Information Update: 12 Jun 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ligand Pharmaceuticals; Pfizer
  • Developer Pfizer; Sermonix Pharmaceuticals
  • Class Antineoplastics; Osteoporosis therapies; Pyrrolidines; Small molecules; Tetrahydronaphthalenes
  • Mechanism of Action Estrogen receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Postmenopausal osteoporosis
  • Preregistration Atrophic vaginitis
  • Phase III Breast cancer
  • Phase II Female sexual dysfunction
  • Research Ovarian cancer
  • No development reported Hypogonadism

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 02 Jun 2018 Pharmacodynamic data from preclinical studies in Breast cancer presented at the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO-2018)
  • 14 Nov 2017 Sermonix Pharmaceuticals plans a phase II trial for Breast cancer (Late-stage disease, Metastatic disease) in Europe and USA (PO) in the fourth quarter of 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top